Picture Berlin Partner Top News from HealthCapital Berlin-Brandenburg 650x100px
Organisation › Details

Ablynx N.V. (Euronext Brussels: ABLX, Nasdaq: ABLX)

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. *


Period Start 2001-01-01 established
  Group Sanofi (Group) [since May 2011]
Products Industry BIOTECH
  Industry 2 Nanobodies® (Ablynx)
Persons Person Moses, Edwin (Ablynx 200603– CEO before non-exec Board Member 200411– before Oxford Asymmetry)
  Person 2 Heylen, Johan (Ablynx 201411– CCO before GSK + Servier + Wyeth)
Region Region Zwijnaarde
  Country Belgium
  Street 21 Technologiepark
  City 9052 Zwijnaarde
  Tel +32-9-262-0000
    Address record changed: 2020-12-02
Basic data Employees n. a.
  Currency EUR
  Annual sales 85,187,000 (income, total (2016) 2016-12-31)
  Profit -1,087,000 (2016-12-31)
  Cash 208,600,000 (2017-09-30)
    * Document for »About Section«: Ablynx N.V.. (7/20/17). "Press Release: Ablynx and Sanofi Enter into a Strategic Collaboration to Develop Nanobody Product Candidates Focused on Immune-mediated Inflammatory Diseases". Ghent.
Record changed: 2023-07-10


Picture EBD Group Biotech Showcase 2024 San Francisco 650x200px

More documents for Sanofi (Group) [since May 2011]

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Special Topic HealthCapital Berlin-Brandenburg 650x300px

» top